News related to Xifaxan (Rifaximin) and/or conditions it is approved for
Salix Presents New Phase II Data Evidence Demonstrating The Clinical Utility Of Rifaximin In Irritable Bowel Syndrome (IBS)
Source: Irritable-Bowel Syndrome News From Medical News Today [2008.10.06]
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced findings from two analyses of a Phase II clinical trial that demonstrate the utility of rifaximin, a non-absorbed, gut-selective antibiotic, in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS).
|
